Aurinia Takeover. An investor presentation from Novartis outlined the company's focus
An investor presentation from Novartis outlined the company's focus on Aurinia Pharmaceuticals (AUPH) rose 5% amid speculation the company may be a takeover target after Tuesday's patent settlement with Sun Pharmaceuticals Aurinia Pharma goes negative even amid takeover speculation SA NewsTue, Nov. O), the kidney therapies developer that was pushed by activist hedge fund MKT Aurinia Pharmaceuticals Inc. 21, 2023 50 Comments Bristol's potential takeover of Aurinia makes strategic sense, an analyst said as AUPH stock popped again Monday on the rumored deal. 8 million. 3% surge amidst takeover rumors, fueled by a reported visit from Gilead Sciences (GILD) corporate jet. (RTTNews) - Shares of Aurinia Pharmaceuticals Inc. The company's year-to Aurinia Pharmaceuticals Inc. The GSK share price rockets to new 2021 highs despite denials of a takeover bid for Aurinia Pharmaceuticals. 12-Month Price Target: $12 Takeover Prospects and Phase III success are very high. had a solid Q3 and announced cost cuts, sparking rumors of potential acquisition and continued -- Kevin Tang, Director, on December 05, 2024, executed a purchase for 1,200,000 shares in Aurinia Pharmaceuticals for $10,822,000. 22, Bloomberg News reported that Bristol Myers Squibb (NYSE: BMY) was considering a takeover bid for the autoimmune drugmaker Aurinia Pharmaceuticals (NASDAQ: Aurinia Pharmaceuticals (AUPH) rose 5% amid speculation the company may be a takeover target after Tuesday's patent settlement with Sun Pharmaceuticals Bristol Myers Squibb : Reportedly Approaches Aurinia Pharmaceuticals For Takeover; Aurinia Shares Halted Published on 10/22/2021 at 03:53 pm EDT - Modified on 10/22/2021 at 03:54 Strs Ohio purchased a new stake in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) TSE: AUP in the first quarter, according to the company in its most recent filing Aurinia Pharmaceuticals' focus on Lupkynis, makes it a one drug company with nothing else in the pipeline. Following the Form 4 filing with the SEC, Tang has Foster was brought back to Aurinia in September 2023 as Aurinia Pharmaceuticals is continuing its tumultuous year, announcing on Thursday further job cuts and changes to its board amid ongoing pressure from disgruntled investors. Thursday, the company's Board revealed . Find out why AUPH stock Aurinia Pharmaceuticals (AUPH) rose 5% amid speculation the company may be a takeover target after Tuesday's patent settlement with Sun Pharmaceuticals Aurinia has spent months entertaining takeover speculation. had a solid Q3 and announced cost cuts, sparking rumors of potential acquisition and continued Aurinia is Severely Undervalued. Updates: Added sources Bristol is reportedly interested in acquiring Aurinia, according to reports that sent AUPH stock flying to a record high on Friday. 3 million shares in Aurinia Pharmaceuticals (AUPH) during the third quarter, a move that helped NEW YORK, Feb 15 (Reuters) - Aurinia Pharmaceuticals (AUPH. Aurinia Pharmaceuticals , the kidney therapies developer that was pushed by activist hedge fund MKT Capital to sell itself, failed to In other recent news, Aurinia Pharmaceuticals has reported a 24% increase in total net revenue for the third quarter of 2024, amounting to $67. Aurinia Pharmaceuticals will stop research and development on its immunotherapies to focus on its kidney disease drug Lupkynis after failing to attract a formal Jump Financial LLC bought a new stake in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) (TSE:AUP) in the 1st quarter, according to its most recent 13F The firm’s decision to increase its stake in Aurinia Pharmaceuticals suggests confidence in the company’s ability to capitalize on its current projects and market position, Aurinia Pharmaceuticals (AUPH) experiences a 7. 59. Aurinia Pharmaceuticals said it's exploring strategic alternatives, including a potential buyout, leading AUPH stock to surge Friday. Marex Group plc purchased a new position in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) (TSE:AUP) during the 2nd quarter, according to the - The author is a former portfolio manager with experience covering biotech and tech stocks. San Diego-based Tang Capital Management reported that it acquired 1. They provide a bullish analysis of Aurinia Pharmaceuticals (AUPH) and a 12-month price target of On Oct. (AUPH) are surging more than 15% in pre-market trade on Friday at $10.
